AIM Vaccine announced that two candidates of COVID-19 mRNA vaccine were approved for clinical trials in Pakistan. One targeting SARS-nCoV-2 mutant is approved for Phase I clinical trial, while the other targeting original COVID-19 virus is approved for Phase III clinical trial of sequential booster vaccination.

The domestic vaccine leader, AIM Vaccine, released a morning notice that its candidate of EV71-CA16 bivalent HFMD vaccine (human diploid cell) recently obtained clinical approval from CDE.

On October 5th, AIM vaccine closed its global sale of shares. A total of 9.714 million H shares were sold globally, with 10% in Hong Kong and 90% abroad including an additional 15% over-allotment option. The offering price was HKD 16.16 per share, with a minimum subscription of 200 shares per lot. AIM Vaccine received massive subscriptions from investors worldwide.
At 9pm on October 6th (Hong Kong time), AIM Vaccine's H shares will be traded on HKSE.

Several domestic COVID-19 mRNA vaccine candidates had entered the clinical stage in the first half of this year. The company utilized the COVID-19 pipeline to quickly establish an mRNA vaccine development and production platform.
Recently, AIM Vaccine released Phase Ⅱ clinical trial data of its self-developed COVID-19 mRNA vaccine, LVRNA009, showing good cellular immune responses and safety.
Notably, this LVRNA009 vaccine also proved effective on Omicron variant according to independent third-party testing results.

AIM Vacin, a wholly-owned subsidiary of AIM Vaccine, obtained the approval from the National Medical Products Administration yesterday (December 1) for carrying out clinical trials of ACYW135 Meningococcus Conjugate Vaccine (MCV4).

According to public information, the inactivated Delta-specific COVID vaccine under R&D by Rong’an Bio, a wholly-owned subsidiary of AIM Vaccine (which is forging ahead with its plan for listing on the HKEX), has now entered the stage of non-clinical animal evaluation, including animal safety evaluation, immunogenicity evaluation and protective evaluation, and Rong’an Bio has begun rolling submission of application documents to the Center for Drug Evaluation (CDE), NMPA.